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ABSTRACT
Background and Objectives: The incidence of postoper-
ative vomiting in patients undergoing laparoscopic chole-
cystectomy is compared in females versus males. The
report also compares the prophylactic action of
ondansetron versus metoclopramide.
Methods: A total of 85 American Society of
Anesthesiologists (ASA) I and II patients were enrolled in
the study. Patients were divided into two groups accord-
ing to sex: Group I 53 females, and Group II 32 males.
After anaesthetic induction, subjects received intravenously
either 4 mg ondansetron or 10 mg metoclopramide.
Results: The incidence of vomiting as well as the fre-
quency of emetic episodes over 24 hours were analyzed in
each group using X2 analysis. Data analysis revealed a sig-
nificantly higher incidence (P<0.05) of postoperative eme-
sis in females 10:53 (18.9%) as compared to males 0:32
(0%). In the male group, no patient vomited postopera-
tively, whether prophylactic ondansetron or metoclo-
pramide was used. While the incidence of emesis in the
female group was lower (P<0.05) in the ondansetron group
(17.6%) than the metoclopramide group (29.6%).
Conclusion: These results may indicate prophylactic
antiemetic therapy in female patients undergoing laparo-
scopic cholecystectomy; ondansetron appears to be superi-
or to metoclopramide.
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INTRODUCTION
Postoperative nausea and vomiting (PONV) has been
called the "Big Little Problem."
1 It can often be the main
cause of prolonged hospital stay. Recent studies have
shown the general incidence of postoperative emesis to be
in the 20-30% range,
2-
6 while the incidence of post-laparo-
scopic vomiting is 35%.
7,
8 Previous investigators have
reported a significantly higher incidence of vomiting after
non-laparoscopic surgery in females as compared to male
adults, including postmenopausal females until the age of
70 years,
2,3,5,
9 suggesting a hormonal pharmacologic basis
for the susceptibility of females to vomiting. Drugs used
in the prevention of postoperative vomiting include anti-
histaminics, anticholinergics, dopamine receptor antago-
nists, and 5HT3 antagonists. The purpose of this study is
to compare in patients undergoing laparoscopic cholecys-
tectomy the incidence of vomiting in females versus
males, and to compare the prophylactic antiemetic action
of ondansetron (a selective 5HT3 antagonist) versus meto-
clopramide (a dopamine receptor antagonist).
METHODS
The study was approved by our hospital research com-
mittee. Approved consent was taken from the patients
preoperatively. American Society of Anesthesiologists
(ASA) Class I and II patients scheduled for laparoscopic
cholecystectomy were chosen. A total of 85 patients were
enrolled in the study. The following data were collected
on all patients: age, weight, history of diabetes, motion
sickness, previous postoperative nausea or vomiting, as
well as days since the last menstrual period (LMP) in
females. Also, anaesthetic techniques, duration of surgery,
and postoperative analgesia were recorded. The patients
were then divided into two groups according to sex.
Group I consisted of 53 females, and Group II consisted
of 32 males. A random number was used to assign
prospectively each patient to receive after induction of
anesthesia either ondansetron 4 mg (A), or metoclo-
pramide 10 mg (B). The staff caring for these patients
were blinded to the study drug received.
All patients were premedicated with meperidine 75 mg,
atropine 0.6 mg and promethazine 25 mg intramuscularly
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Table 1.
Demographic Data.
Characteristics
Age (yrs)
Weight (kg)
History of Motion sickness
History of Diabetes
Number of days since LMP
PREVIOUS ANAESTHESIA
None
Without nausea & vomiting
With nausea & vomiting
Duration of surgery (min.)
Need for analgesics
TOTAL
FEMALE
Ondansetron (A)
48.3 ± 16.6
68.3 ± 10.7
2
1
2-45 (16 ± 14)
10
15
1
102.6 ± 22.9
11
26
Metoclopramide (B)
41.3 ± 13.4
69.1 ± 11.6
2
1
1-30 (13.2 ± 9.3)
10
14
3
90.9 ± 28.7
11
27
MALE
Ondansetron (A)
47.1 ± 12.7
87.5 ± 18.0
0
2
-
5
12
1
103.3 ± 17.8
9
18
Metocloramide (B)
43.5 ± 9.8
84.3 ± 18.8
1
-
8
5
1
115.8 ± 28.9
7
14
45 minutes prior to the induction of anesthesia. After
standard monitoring (EKG, noninvasive blood pressure
and oximetry) was applied, all patients were induced with
thiopentone 5 mg/kg, fentanyl 2 μg/kg and vecuronium
0.1 mg/kg. Following induction of anesthesia, patients
received randomly either ondansetron 4 mg (A) or meto-
clopramide 10 mg (B). Anesthesia was maintained by
N20:02 mixture (2:1) and supplementary doses of vecuro-
nium. All patients had a nasogastric tube inserted intra-
operatively that was removed at the end of surgery. The
duration of operation was recorded and neuromuscular
blockade was reversed by a mixture of neostigmine 0.05
mg/kg and atropine 0.02 mg/kg. In the recovery room,
an independent blinded observer recorded emetic
episodes, vital signs, oxygen saturation and pain scores
for two hours postoperatively. Drugs administered, such
as narcotics or antiemetics, were also recorded.
Table 2.
Incidence of Vomiting.
Total
Females
Males
Number
53
32
Vomiting
10
0
No Vomiting
43
32
After two hours, patients were discharged to the floor,
where they were followed up to 24 hours by another
independent observer; the number of patients who vom-
ited was recorded in each group. The degree of pain and
medications administered were also recorded. The inci-
dence of emetic episodes over 24 hours were analyzed in
each group, using X2 analysis at 95% confidence interval.
P<0.05 was considered significant.
RESULTS
Laparoscopic cholecystectomy during the study period
was more frequent in females than in males.
There were no differences between study groups with
respect to age, anaesthetic technique, duration of opera-
tion, diabetes, days since the last menstrual period in
females, or history of previous postoperative nausea and
vomiting as well as the need for postoperative analgesics
(Table 1).
All recorded episodes of vomiting were associated with
the forceful expulsion of gastric contents; none of the data
represents an episode of retching. As shown in Table 2,
the incidence of emesis was significantly higher in the
female group than in the male group (P<0.05). In the
male group, no patient vomited postoperatively, whether
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Incidence of Vomiting.
Females
Total Number
Ondansetron (A)
Metoclopramide (B)
26
27
Vomiting
2
8
No Vomiting
24
19
prophylactic ondansetron or metoclopramide was used.
In the female group, the incidence of postoperative eme-
sis was significantly lower (P<0.05) in the ondansetron
group than the metoclopramide group (Table 3).
DISCUSSION
The present study shows in patients undergoing laparo-
scopic cholecystectomy that females have a significantly
higher incidence of postoperative vomiting than males.
This finding confirms the gender difference that exists
between adult males and females below the age of 70
years, that was published many years ago by Bellville
2 in
patients undergoing non-laparoscopic surgery under gen-
eral anesthesia. Variations in serum gonadotropin (or
other hormonal) levels may be a factor in the higher inci-
dence of postoperative vomiting in females.
Gonadotropin level is known to rise at menopause for
several years before falling, which coincides with the age
of 70 years when the gonadotropin level falls. At this age,
the incidence of vomiting in females approaches that seen
in males.
2 In males, our report shows that the incidence
and severity of vomiting is low, whether metoclopramide
or ondansetron is used as a prophylactic antiemetic.
However, in females, where there is a higher incidence of
vomiting, prophylactic administration of ondansetron
appears to be superior to metoclopramide.
The low incidence of vomiting in the present study, as
compared to previous studies, may be attributed to the
fact that we considered only patients who vomited, and
did not include nausea, which can be subjective. Also,
our patients were premedicated with promethazine and
atropine. Atropine premedication has been shown to
decrease the incidence of vomiting,
1
0 and promethazine
(an antihistaminic with both antidopaminergic and
antimuscarinic action) has been also shown to decrease
the incidence of postoperative vomiting.
5
Postoperative vomiting is multifactorial in origin; both the
type of anesthesia and surgery, duration of surgery, along
with postoperative pain or analgesic (narcotics) contribute
to its etiology. The mechanisms can be either central or
peripheral.
9,1
1 There are four major neurotransmitters
which play a role in mediating the emetic response:
dopaminergic, histaminergic (H1), cholinergic muscarinic
and 5HT3.
9,1
1 Therefore, drugs used for the prevention of
postoperative vomiting are usually antihistaminics, anti-
cholinergics, and dopamine receptor antagonists.
12,1
3
However, these drugs possess clinically significant unto-
ward side-effects (sedation, dry mouth, dysphoria and
extrapyramidal symptoms) which often may limit their
use, especially in ambulatory surgery.
Ondansetron, a selective antagonist of 5HT3 receptors,
has been effectively used for the prevention of
chemotherapy-induced emesis. Chemotherapy-induced
emesis is secondary to the release 5HT3 from the shed-
ding of the mucosa of the gut during chemotherapy.
1
4
Also, ondansetron has been shown in many recent stud-
ies to be effective for the prevention of nausea and vom-
iting in high risk operations such as laparoscopic
surgery,
1
5 post-strabismus repair in children
1
6 and gyne-
cologic surgery,
1
7 with little side effects.
18,1
9
Metoclopramide, on the other hand, blocks dopamine
receptors at the chemoreceptor trigger zone (CTZ); also, it
increases lower esophageal sphincter tone and enhances
gastric and small bowel motility.
9 However, metoclo-
pramide failed to reduce the incidence of PONV after
major gynecologic surgery
12,1
3 and laparoscopic surgery.
2
0
The short duration of action of metoclopramide may
explain its lack of efficacy in preventing PONV.
The present report has shown that prophylactic
ondansetron is superior to metoclopramide in patients
undergoing laparoscopic cholecystectomy. Intra-abdomi-
nal operations are more associated with postoperative
vomiting than extra-abdominal operations. Manipulations
and traction on the gut during abdominal surgery dis-
charge vagal and splanchnic afferents to the central ner-
vous system.
1
1 In addition to this mechanism, surgical
manipulation of the intestine also induces release of 5HT3
from the enterochromaffin cells.
1
1 That is why
ondansetron, a selective 5HT3 antagonist, can be the
antiemetic of choice following intra-abdominal surgery.
In conclusion, the incidence of post-laparoscopic chole-
cystectomy vomiting is significantly higher in females than
in males. Because of the high incidence of vomiting in
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females, prophylactic antiemetic therapy may be indicat-
ed. Ondansetron prophylaxis appears to be superior to
metoclopramide.
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